na na na
(2022-11-30 23:54):
#paper doi: 10.1186/s13148-021-01210-6. Clin Epigenetics. 2021 Dec 18,Meyer B;Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer; 为避免新辅助化疗(NAC)用于三阴性乳腺癌(TNBC)术前的治疗所产生的化学毒性，需要准确的生物标志物来进行个体化预测。作者对术前TNBC活检样本进行了全基因组DNA甲基化分析，找到9个诊断时与NAC反应相关的显著差异甲基化区域(DMRs)。其中4种DMRs与TNBC总生存率显著相关(P < 0.05)。文章的重要意义不仅在于找到了TNBC的新辅助化疗预后标志物，更强调了DNA甲基化作为生物标志物在预测NAC反应方面的潜力。
Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Abstract:
Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
Keywords:
DNA methylation,
Epigenetics,
Methylome,
Neoadjuvant chemotherapy,
Triple-negative breast cancer